How to market a HealthTech startup between seed and Series A

The seed to Series A gap is a proof problem, not an awareness problem

At seed, investors backed a team and a wedge. At Series A, they need evidence that the wedge is a business. That means the marketing function's job for the next twelve to eighteen months is not to build a brand, it is to build a repeatable, explainable pipeline that a Series A partner can diligence in a single afternoon.

Founders waste this window on activity that looks like marketing but does not build a fundable story: generic content calendars, rebrands, conference sponsorships with no attribution. None of it survives a data room review. What survives is a small number of channels with a clean line from spend to qualified pipeline to closed revenue, run long enough to show a trend, not a spike.

Pick the two channels that map to your actual buying cycle

HealthTech sells into one of three buyer types, and each has a different marketing motion: clinicians and care teams (long trust cycles, KOL and peer validation matter more than ads), health system and hospital procurement (committee based, RFP driven, twelve to eighteen month cycles), or payers and employers (actuarial proof and pilot data before anything else). Pick your primary buyer and build the two channels that match its decision process, not the two channels that are easiest to run.

For clinician and provider sales, that usually means a founder-led content and community motion (peer-reviewed adjacent commentary, conference presence with a real speaking slot, referenceable pilot sites) paired with targeted outbound to a named account list built from your ICP's actual org chart, not a purchased list.

• Provider sale: founder content plus targeted outbound to named accounts
• Payer or employer sale: pilot data plus direct relationships through benefits consultants
• Consumer or DTC health: paid acquisition with unit economics proven at small scale before you raise spend

Build the metrics stack before you need it

The number one reason HealthTech founders stumble in Series A diligence is that they cannot answer basic pipeline questions cleanly: what is your CAC by channel, what is your sales cycle length by segment, what percentage of pipeline came from inbound versus outbound versus referral, and what is your logo retention after the first renewal. If you are not tracking these from month one of your seed spend, you are building the story backwards.

Set up attribution now, even if it is a simple CRM field and a monthly spreadsheet reconciliation. Investors do not expect Silicon Valley grade marketing ops at seed. They do expect you to know your numbers cold and to show the same numbers, consistently, across three consecutive board decks.

What to deliberately not do yet

Do not hire a VP of Marketing before you have a channel that works. Do not run a rebrand. Do not chase press for its own sake, a TechCrunch mention does not move a hospital procurement committee. Do not build a twelve-person content team producing SEO blog posts with no connection to your buyer's actual search behaviour, which in regulated HealthTech is often navigating through KOLs and peer networks rather than Google.

Every dollar spent between seed and Series A should be traceable to a hypothesis about your growth engine that you can defend in a partner meeting.